Study of new drug combo for advanced stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab/tuvonralimab) plus chemotherapy (XELOX) in people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has low PD-L1 levels. It aims to see if this treatment can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your cancer is HER2-negative (a specific protein test result) and has low PD-L1 expression (a marker that helps predict response to immunotherapy).
- You have not had any previous treatment for advanced disease, or if you had chemotherapy before surgery (neoadjuvant/adjuvant), your cancer came back more than 6 months after that treatment ended.
- You are in good enough physical condition to be up and about (ECOG score 0 or 1).
- You do not have any major health issues like uncontrolled infections, autoimmune diseases, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (QL1706) and chemotherapy before surgery for people with early-stage stomach cancer. The goal is to see if this approach shrinks the tumor and improves surgical outcomes.
This study tests a combination of two immunotherapy drugs plus chemotherapy before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer who have not had prior treatment. It aims to see if this combination can shrink tumors and help people live longer.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with chemotherapy (SOX) and radiation for stomach cancer that hasn't been treated before. The goal is to see if this approach can shrink tumors and help you live longer.
This trial is testing a combination of immunotherapy, anti-angiogenic (blood vessel blocker) therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't spread yet. It is for those whose tumors have a low PD-L1 score and who haven't had treatment for the advanced cancer before.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy for stomach cancer. The goal is to see if this combination can help shrink tumors and improve outcomes better than chemotherapy alone.
Hear when a new HER2-negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.